NEW YORK, September 14, 2024--Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its ...

4 and BA.5 subvariants of Omicron and said if... ByReuters • Aug 24, 2022 Pfizer's COVID vaccine 73.2% effective in kids under 5, new data shows (Reuters) - Pfizer Inc (NYSE:PFE) and BioNTech's ...

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with ...

Pfizer Inc.’s stock rose 2.7% early Tuesday ... plan and raised its revenue and profit guidance for the year. New York-based Pfizer had net income of $41 million, or 1 cent a share, for the ...

NEW YORK - Pfizer Inc. (NYSE ... a high EBITDA valuation multiple, Pfizer's PEG Ratio for the last twelve months as of Q2 2024 is 0.58, suggesting that the stock may be undervalued based on ...

Pfizer Inc. (NYSE: PFE) experienced a notable uptick in its stock price during Monday’s trading session, climbing by +2.12% to reach $29.89 at 11:10 AM EDT. This positive movement comes in the wake of ...

Shares of Pfizer Inc. PFE shed 0.27% to $29.75 Wednesday, on what proved to be an all-around dismal trading session for the ...

In a report released today, Akash Tewari from Jefferies assigned a Buy rating to Pfizer (PFE – Research Report), with a price target of ...

However, the Hold rating suggests that while Pfizer’s financial and operational strategies are solid, the potential for significant stock appreciation ... in New York, NY. Read More on PFE ...

The New York-based pharma giant generated adjusted earnings of $0.60 a share on revenue of $13.28B that grew 2.2% ...

But is the stock still worth buying in hopes of a recovery over the long term? To answer that question in more detail, let's put this setback into context.

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Pfizer PFE in the ...